Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BP pays Auchincloss £8m in 2023, claws back £1.8m from Looney

(Sharecast News) - BP chief executive officer Martin Auchincloss was paid £8m for his services in a particularly prosperous year, it was revealed on Friday, as it managed to claw back a further £1.8m from its former head Bernard Looney. The FTSE 100 oil giant said Auchincloss received a base salary of £1.6m for 2023, and a performance-based bonus of £6.5m.

Auchincloss, who was previously the company's chief financial officer, assumed the interim role in September before being officially named CEO in January.

Former CEO Bernard Looney, who resigned in September due to personal relationship disclosures, received £1.2m in pay until his departure.

However, the company disclosed the cancellation of £3m in bonuses and share awards, resulting in a negative overall pay of -£1.8m for the year.

According to City AM, that reduction followed a previous £31m cut from Looney's pay packet in 2023.

BP's financial results for 2023, released last month, showed a profit of £10.8bn, which was a decline from the prior year's £21.6bn amid cooling oil and gas prices.

Auchincloss attributed the performance to strong operational delivery across the business.

At 1027 GMT, shares in BP were up 0.49% at 478.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.